GLT8D1

GLT8D1 is a Mn²⁺-dependent, UDP-galactose-utilizing glycosyltransferase that adopts a GT-A fold with a retaining catalytic mechanism and transfers galactose onto N-acetylgalactosamine substrates (PMID:38066107). Its enzymatic activity N-glycosylates substrates including CD133, preventing their endosomal–lysosomal degradation and thereby sustaining Wnt/β-catenin signaling, glioma stem cell self-renewal, and tumor cell migration (PMID:35301431, PMID:35198895). GLT8D1 also regulates neural stem cell proliferation and differentiation, and modulates synaptic transmission in neurons (PMID:29483533). ALS-associated missense mutations (R92C, G78W) at the substrate-binding site diminish enzymatic activity and cause motor neuron toxicity in zebrafish, establishing GLT8D1 as a causative gene for amyotrophic lateral sclerosis (PMID:30811981).

1. 2018 Medium

   Before GLT8D1's molecular function was characterized, loss-of-function studies established that it is required for normal neural stem cell differentiation and synaptic function, placing it in a neurodevelopmental context.

   Evidence siRNA knockdown in neural stem cells and neurons with proliferation, differentiation, and electrophysiology readouts

   PMID:29483533

   Open questions at the time

   • Molecular substrates mediating the neural phenotypes were not identified
   • No rescue experiment with catalytically active GLT8D1 was performed
   • Whether the phenotype depends on glycosyltransferase activity versus a scaffolding role was untested
2. 2019 High

   Identification of GLT8D1 as an ALS gene established that its glycosyltransferase activity is disease-relevant: R92C and G78W mutations map to the substrate-binding site, reduce enzyme activity, cause cytotoxicity in vitro, and produce motor deficits in zebrafish.

   Evidence Exome sequencing of ALS families, in vitro enzymatic assay on mutant vs. wild-type protein, cytotoxicity assays, zebrafish motor phenotyping

   PMID:30811981

   Open questions at the time

   • The endogenous substrates whose aberrant glycosylation leads to motor neuron death were not identified
   • Whether loss of function or gain of toxic function drives neuronal toxicity was not resolved
   • Mammalian motor neuron models were not tested
3. 2022 High

   Two studies resolved the functional output of GLT8D1's enzymatic activity in glioma: it N-glycosylates CD133 to prevent lysosomal degradation, sustains Wnt/β-catenin signaling and glioma stem cell self-renewal, and its catalytic activity is required for tumor cell migration.

   Evidence Co-immunoprecipitation of GLT8D1–CD133, N-glycosylation assays, active-site mutagenesis coupled to migration assays, in vivo xenograft validation, LC-MS/MS interactome

   PMID:35198895 PMID:35301431

   Open questions at the time

   • Whether CD133 glycosylation accounts for the migration phenotype or whether cytoskeletal substrates identified by MS are independently required
   • The glycan structure installed by GLT8D1 on CD133 was not defined at the glycomic level
   • HIF-1α–mediated transcriptional induction was shown but upstream signaling to HIF-1α was not dissected
4. 2023 High

   Biochemical reconstitution definitively characterized GLT8D1 as a UDP-galactose-dependent galactosyltransferase with a GT-A fold and retaining mechanism, resolving its catalytic identity.

   Evidence Purified recombinant GLT8D1, in vitro glycosyltransferase assay with UDP-galactose and GalNAc, differential scanning fluorimetry showing Mn²⁺/UDP stabilization, structural modeling

   PMID:38066107

   Open questions at the time

   • No crystal or cryo-EM structure has been determined experimentally
   • The full physiological acceptor substrate specificity beyond GalNAc and CD133 remains undefined
   • Whether the enzyme operates on glycolipids in addition to glycoproteins is unknown

• Key unresolved questions include the identity of GLT8D1's substrates in motor neurons that explain ALS pathogenesis, the structural basis of substrate recognition, and whether its neural and oncogenic functions converge on a shared glycosylation-dependent signaling mechanism.
• No ALS-relevant neuronal substrate has been identified
• No experimental three-dimensional structure is available
• The relationship between neural stem cell and glioma stem cell phenotypes at the substrate level is unexplored